权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Microenvironment mediated drug resistance in melanoma.

微环境介导黑色素瘤耐药性。

基本信息

批准号：
8851995
负责人：
Keiran Smalley
金额：
$ 34.65万
依托单位：
H. LEE MOFFITT CANCER CTR & RES INST
依托单位国家：
美国
项目类别：
财政年份：
2011
资助国家：
美国
起止时间：
2011-08-01 至 2017-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8851995
关键词：
Address Adhesions Adoption Apoptosis BRAF gene Belief Blood Vessels Bypass Cell Line Cells Clinic Clinical Clinical Trials Coculture Techniques Collagen Data Deposition Drug resistance Effectiveness Endothelial Cells Environment Extracellular Matrix Fibroblasts Fibronectins Future Genotype Goals Growth Growth Factor Heterogeneity Human Integrins Knowledge Laminin Lead Life Ligands MEKs Mediating Melanoma Cell Minor Modeling Mutate PTEN gene Patients Phase Phenotype Platelet-Derived Growth Factor Population Proliferating Proto-Oncogene Proteins c-akt Relapse Research Resistance Role Series Signal Transduction Specimen Testing Therapeutic Vascular Endothelial Growth Factors Work Xenograft Model angiogenesis autocrine cell motility improved in vivo inhibitor/antagonist melanoma neoplastic cell notch protein novel novel therapeutics prevent research study resistance mechanism response small molecule therapeutic development therapeutic target tumor tumor eradication tumor microenvironment

项目摘要

DESCRIPTION (provided by applicant): The long-term goals of this work are the development of therapeutic strategies to improve the survival of patients with disseminated melanoma. There is already good evidence that mutated BRAF is a bona fide therapeutic target in over 50% of melanomas, and that impressive but short-lived clinical responses can be achieved with small molecule BRAF inhibitors (such as PLX4032). Clinically, BRAF inhibitor resistance follows a course where tumor regression is followed by quiescence and eventual relapse. The overall hypothesis is that BRAF inhibition remodels both the melanoma and host microenvironments to provide a protective "sanctuary" for the minor populations of melanoma cells that escape therapy. Conceptually, it is believed that there are at least two forms of environment-mediated therapeutic escape; the first, defined as "tumor intrinsic", was observed in melanoma cell lines that lack PTEN function (PTEN-) and involved the establishment of autocrine integrin/extracellular matrix (ECM) signaling loops that bypass BRAF signaling and downregulate apoptosis. The second was host-mediated, where BRAF inhibition in primary human fibroblasts paradoxically activated AKT and MEK signaling leading to the expression of PDGF-D, VEGF and the Notch ligand Jagged as well as increasing the deposition of fibronectin, collagens and laminin. The first aim will investigate how BRAF inhibition leads to the acquisition of autocrine ECM-driven signaling loops and will determine how these altered adhesion signals "re-wire" the signaling of the escaping population and leads to the adoption of a phenotype that is slow-proliferating, apoptosis resistant and pro-invasive. We will then test whether therapeutic targeting of the melanoma cell/ECM interactions ameliorates intrinsic resistance by preventing the microenvironment- mediated reorganization of the melanoma signaling network. In aim 2, we will test the hypothesis that BRAF inhibition activates host fibroblasts leading to the creation of a "refuge" vascular microenvironment that allows PTEN+ melanoma cells to escape from therapy. We will address how BRAF inhibition in normal host fibroblasts leads to the establishment of autocrine growth factor signaling loops that drives their activation. We will then use novel 3D melanoma/fibroblast/endothelial cell co-culture and in vivo xenograft models to investigate the mechanisms by which inhibition of BRAF in fibroblasts drives the angiogenic response and will elucidate the role of the vascular niche as a protective "sanctuary" for the escaping melanoma cells. It is expected that knowledge gained from this work will provide novel therapeutic strategies for overcoming BRAF inhibitor resistance in the clinic. 1

描述（由申请人提供）：这项工作的长期目标是开发治疗策略，以提高播散性黑色素瘤患者的生存率。已经有很好的证据表明，突变的BRAF在超过50%的黑色素瘤中是真正的治疗靶点，并且使用小分子BRAF抑制剂（如PLX 4032）可以实现令人印象深刻但短暂的临床反应。在临床上，BRAF抑制剂耐药性遵循肿瘤消退之后是静止和最终复发的过程。总的假设是BRAF抑制重塑黑色素瘤和宿主微环境，为逃避治疗的少数黑色素瘤细胞群体提供保护性“避难所”。从概念上讲，认为存在至少两种形式的环境介导的治疗逃逸;第一种被定义为“肿瘤内在的”，在缺乏PTEN功能（PTEN-）的黑素瘤细胞系中观察到，并且涉及建立绕过BRAF信号传导并下调细胞凋亡的自分泌整联蛋白/细胞外基质（ECM）信号传导环。第二种是宿主介导的，其中原代人成纤维细胞中的BRAF抑制矛盾地激活AKT和MEK信号传导，导致PDGF-D、VEGF和Notch配体Jagged的表达以及增加纤连蛋白、胶原蛋白和层粘连蛋白的沉积。第一个目标将研究BRAF抑制如何导致获得自分泌ECM驱动的信号循环，并将确定这些改变的粘附信号如何“重新连接”逃逸群体的信号传导，并导致采用缓慢增殖、抗凋亡和促侵袭的表型。然后，我们将测试黑色素瘤细胞/ECM相互作用的治疗靶向是否通过阻止黑色素瘤信号传导网络的微环境介导的重组来改善内在抗性。在目标2中，我们将测试这样的假设：BRAF抑制激活宿主成纤维细胞，导致创建“避难所”血管微环境，允许PTEN+黑色素瘤细胞逃避治疗。我们将讨论如何在正常宿主成纤维细胞BRAF抑制导致自分泌生长因子信号环的建立，驱动其激活。然后，我们将使用新的3D黑色素瘤/成纤维细胞/内皮细胞共培养和体内异种移植模型来研究成纤维细胞中BRAF抑制驱动血管生成反应的机制，并将阐明血管小生境作为逃逸黑色素瘤细胞的保护性“避难所”的作用。预计从这项工作中获得的知识将为克服临床中的BRAF抑制剂耐药性提供新的治疗策略。1

项目成果

期刊论文数量（24）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Activity-Based Protein Profiling Shows Heterogeneous Signaling Adaptations to BRAF Inhibition.

DOI：
10.1021/acs.jproteome.6b00613
发表时间：
2016-12-02
期刊：
Journal of proteome research
影响因子：
4.4
作者：
Sharma R;Fedorenko I;Spence PT;Sondak VK;Smalley KS;Koomen JM
通讯作者：
Koomen JM

The role of phenotypic plasticity in the escape of cancer cells from targeted therapy.

DOI：
10.1016/j.bcp.2016.06.014
发表时间：
2016-12-15
期刊：
BIOCHEMICAL PHARMACOLOGY
影响因子：
5.8
作者：
Emmons, Michael F.;Faiao-Flores, Fernanda;Smalley, Keiran S. M.
通讯作者：
Smalley, Keiran S. M.

Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells.

DOI：
10.1038/onc.2015.188
发表时间：
2016-03-10
期刊：
Oncogene
影响因子：
8
作者：
Fedorenko IV;Abel EV;Koomen JM;Fang B;Wood ER;Chen YA;Fisher KJ;Iyengar S;Dahlman KB;Wargo JA;Flaherty KT;Sosman JA;Sondak VK;Messina JL;Gibney GT;Smalley KS
通讯作者：
Smalley KS

Combination Therapies for Melanoma: A New Standard of Care?